SLC5A2 and type 2 diabetes mellitus: However, as per D’Andrea et al., despite the initial concerns that employing SGLT2 inhibitors at elevated HbA1c levels might pose an increased risk, it is now established that individuals with T2DM can experience advantages from SGLT2 inhibitor usage irrespective of their glycemic control, and there is no heightened risk of adverse effects in those with increased HbA1c levels [227].